Duke Energy Corp vs Vaxcyte Inc. Common Stock — how do they compare? Duke Energy Corp trades at $120.33 (market cap $92.15B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Duke Energy Corp is far larger — about 8.8× Vaxcyte Inc. Common Stock's market cap, and Duke Energy Corp pays a 3.67% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 75 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| DUK | PCVX | |
|---|---|---|
Market Cap | $92.15B | $10.51B |
Volume | 3,498,824 | 2,644,694 |
Sector | Utilities | Health |
52-Week High | $133.46 | $73.82 |
52-Week Low | $113.23 | $40.32 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $184.66B | $9.14B |
Dividend Yield | 3.67% | — |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $119.64, up 1.66% on the day, with a bullish technical signal despite some overbought RSI readings. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $32.24B and $4.97B in 2025, respectively, while maintaining strong profitability margins. Recent news highlights dividend declarations and data center growth opportunities.
The outlook for DUK is positive, supported by consistent earnings beats, a solid dividend yield, and strategic positioning in data center contracts. Risks include high debt levels, rising interest rates impacting utility stocks, and execution challenges in capital-intensive projects. Analyst consensus leans hold with a $131.50 price target, suggesting moderate upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →